443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections

MLA

Thomas L Walsh, et al. “443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections.” Open Forum Infectious Diseases, vol. 6, no. Suppl 2, Oct. 2019, p. S219. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c8019922ff2c8e2b77263b51646c348d&authtype=sso&custid=ns315887.

APA

Thomas L Walsh, Kathleen R Sheridan, Maha Assi, Mark Redell, Jill Massey, Anurag Gandhi, Ivan Soosaipillai, Markian Bochan, David Chansolme, & Miguel Sierra-Hoffman. (2019). 443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections. Open Forum Infectious Diseases, 6(Suppl 2), S219.

Chicago

Thomas L Walsh, Kathleen R Sheridan, Maha Assi, Mark Redell, Jill Massey, Anurag Gandhi, Ivan Soosaipillai, Markian Bochan, David Chansolme, and Miguel Sierra-Hoffman. 2019. “443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections.” Open Forum Infectious Diseases 6 (Suppl 2): S219. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....c8019922ff2c8e2b77263b51646c348d&authtype=sso&custid=ns315887.